What is RegCell?
RegCell operates at the intersection of advanced immunology and therapeutic platform development. The company is dedicated to the mission of restoring self-tolerance to the immune system, a critical mechanism that, when compromised, leads to a wide array of autoimmune disorders. By leveraging sophisticated biological research, RegCell aims to move beyond symptomatic treatment, instead targeting the underlying drivers of immune dysfunction. Based in the biotech hub of Emeryville, California, the firm is currently scaling its research operations to validate its therapeutic candidates, supported by a robust syndicate of international investors who recognize the potential for high-impact clinical breakthroughs in the life sciences sector.
How much funding has RegCell raised?
RegCell has raised a total of $89.8M across 2 funding rounds:
Other Financing Round
$37.3M
Angel/Seed
$8.5M
Angel/Seed (2025): $8.5M with participation from Celadon Partners, University of Tokyo Edge Capital Partners, Fast Track Initiative, and Mitsubishi UFJ Capital
Other Financing Round (2025): $37.3M led by Japan’s Agency for Medical Research and Development
Key Investors in RegCell
Fast Track Initiative
A healthcare-focused venture capital firm with extensive experience in early-stage life science startups, providing hands-on operational support and R&D strategy.
Mitsubishi UFJ Capital
A prominent investment firm that provides deep insight into the Japanese market and has a track record of financing over 1,000 companies.
Celadon Partners
An Asian private equity firm specializing in venture capital investments, focusing on transformative innovations and long-term value creation in B2B and financial sectors.
What's next for RegCell?
With this latest infusion of capital, RegCell is well-positioned to accelerate its R&D pipeline and transition toward critical clinical milestones. The strategic nature of this financing suggests a focus on expanding operational capacity and strengthening the company's intellectual property portfolio. As the firm continues to refine its therapeutic platforms, the focus will likely shift toward establishing key industry partnerships and navigating the regulatory landscape to bring its novel treatments to market. The involvement of specialized healthcare investors provides not only the necessary financial runway but also the operational expertise required to scale in the highly competitive global biotechnology landscape.
See full RegCell company page
